Merck KGaA (MRK) PT Set at €100.00 by J P Morgan Chase & Co
Merck KGaA (FRA:MRK) has been given a €100.00 ($119.05) price target by J P Morgan Chase & Co in a research report issued on Tuesday. The firm presently has a “neutral” rating on the healthcare company’s stock. J P Morgan Chase & Co’s target price points to a potential upside of 10.30% from the stock’s previous close.
MRK has been the topic of a number of other reports. Oddo Bhf set a €125.00 ($148.81) price objective on Merck KGaA and gave the company a “buy” rating in a report on Friday, November 10th. Citigroup set a €123.00 ($146.43) price objective on Merck KGaA and gave the company a “buy” rating in a report on Monday, September 25th. Goldman Sachs Group set a €105.00 ($125.00) price objective on Merck KGaA and gave the company a “neutral” rating in a report on Tuesday, September 19th. Kepler Capital Markets set a €119.00 ($141.67) price objective on Merck KGaA and gave the company a “buy” rating in a report on Thursday, September 21st. Finally, Deutsche Bank set a €99.00 ($117.86) price objective on Merck KGaA and gave the company a “neutral” rating in a report on Friday, November 10th. Twelve equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of €107.81 ($128.34).
Shares of Merck KGaA (FRA MRK) opened at €90.27 ($107.46) on Tuesday. Merck KGaA has a 52 week low of €87.33 ($103.96) and a 52 week high of €115.00 ($136.90).
COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/12/14/merck-kgaa-mrk-pt-set-at-100-00-by-j-p-morgan-chase-co.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.